The estimated Net Worth of Jason Haas is at least $47.1 mil dollars as of 31 March 2024. Mr Haas owns over 15,333 units of Syros Pharmaceuticals stock worth over $47,147 and over the last 3 years he sold SYRS stock worth over $0.
Mr has made over 3 trades of the Syros Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 15,333 units of SYRS stock worth $24,686 on 31 March 2024.
The largest trade he's ever made was exercising 18,875 units of Syros Pharmaceuticals stock on 31 October 2023 worth over $30,389. On average, Mr trades about 3,621 units every 37 days since 2021. As of 31 March 2024 he still owns at least 29,284 units of Syros Pharmaceuticals stock.
You can see the complete history of Mr Haas stock trades at the bottom of the page.
Jason Haas is the Chief Financial Officer at Syros Pharmaceuticals.
Jason's mailing address filed with the SEC is 555 HERITAGE DRIVE, SUITE 200, JUPITER, FL, 33458.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju y Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: